Company intelligence / Profile preview
Appello Pharmaceuticals
Nashville, Tennessee, USAappellopharma.com ↗
- Ownership
- Private
- Employees
- ~49
- Development stage
- Phase 1
01
Overview
Appello Pharmaceuticals is advancing its lead compound AP-472 through clinical trials for Parkinson's disease treatment. The company completed a Phase 1a study where AP-472 was detected in the cerebrospinal fluid of healthy volunteers at levels predicted to be required for efficacy, indicating the drug is brain penetrant. A Phase 1b trial was planned to enroll approximately 20 Parkinson's disease patients with results expected in early 2023.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Vanderbilt University's Warren Center for Neuroscience Drug Discovery (WCNDD)
Beyond the preview
Go deeper on Appello Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Appello Pharmaceuticals.